Skip to main content

Table 2 Factors associated with imaging biomarkers of neurodegeneration related to Alzheimer’s disease

From: The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer’s disease

Dependent variable Model Independent variables B estimate (95% CI) Standardized β P valueb
Hippocampal volume I-1 Age − 23.01 (− 28.71~ − 17.30) − 0.414 < 0.001**
Gender 96.58 (− 9.99~203.15) 0.099 0.076
Educational level − 3.93 (− 15.21~7.35) − 0.038 0.494
APOEε4 − 174.78 (− 331.62~ − 17.93) − 0.114 0.029*
Dyslipidemia 167.05 (58.20~275.89) 0.159 0.003**
Hippocampal volume I-2 Age − 22.67 (− 28.45~ − 16.88) − 0.408 < 0.001**
Gender 89.25 (−17.90~196.40) 0.091 0.102
Educational level − 1.97 (− 13.24~9.29) − 0.019 0.731
APOEε4 − 158.91 (− 316.83~ − 1.00) − 0.104 0.049*
Dyslipidemia: Group 3a 90.55 (9.06~172.04) 0.116 0.030*
White matter hyperintensity II Age 0.024 (0.017~0.032) 0.345 < 0.001**
Gender − 0.129 (− 0.268~0.010) − 0.104 0.068
Educational level − 0.004 (− 0.019~0.011) − 0.030 0.601
APOEε4 0.094 (−0.111~0.299) 0.048 0.4368
Hypertension 0.174 (0.040~0.309) 0.139 0.011*
Statin therapy − 0.236 (− 0.386~ − 0.086) − 0.167 0.002**
  1. Age, gender, educational level, and APOEε4 carrier status were adjusted as covariates in all linear regression models. Models were built by stepwise selection method with P value of entry = 0.1 and stay = 0.2
  2. Abbreviations: APOE apolipoprotein E, LDL low-density lipoprotein
  3. aDyslipidemia status was divided into four groups according to disease and treatment status: subjects without dyslipidemia (group 1), subjects with known dyslipidemia and received statin therapy (group 2), subjects with known dyslipidemia and not under medication control (group 3), and subjects unaware of their dyslipidemia status before enrollment (group 4)
  4. b* = P < 0.05, ** = P < 0.01